Immunotherapy efficacy and patient’s sex in advanced or metastatic non-small cell lung cancer: a systematic review and network meta-analysis

Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1), alone or combined with chemotherapy (CT), are the gold standard for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Guidelines strongly recommend anti-PD-1/PD-L1 (anti-PD-(L)1) monotherapy when PD-L1 tumor proportion score (TPS) is ≥ 50%. Emerging evidence suggests that also sex may influence ICI efficacy. The objective of this study was to estimate sex-based differences in the relative efficacy between anti-PD-(L)1 + CT and anti-PD-(L)1 monotherapy. This study is a systematic review and network meta-analysis of phase II/III randomized controlled trials evaluating ICI-based regimens containing anti-PD-(L)1 or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), alone or combined with CT, versus any control arm in advanced NSCLC, focusing on sex-specific treatment effects. Fifty trials including 29,002 patients were analyzed. For each treatment comparison, differences between males and females were assessed by calculating the ratio of hazard ratios (HRs) for males (HR-M) versus females (HR-F), separately for overall survival (OS) and progression-free survival (PFS). For OS, anti-PD-(L)1 + CT significantly improved outcomes in females compared to anti-PD-(L)1 monotherapy [HR-F (95% CI) = 0.84 (0.73–0.96)], while no significant difference was seen in males [HR-M = 0.99 (0.90–1.10)]. The pooled ratio of hazard ratios favored females [Ratio-HR = 1.20 (1.01–1.42), p = 0.04]. Similar trends were observed for PFS. Anti-CTLA-4, whether combined with CT, anti-PD-(L)1, or both, did not yield superior outcomes compared to anti-PD-(L)1 monotherapy. These findings suggest that sex may modulate the efficacy of ICI in advanced NSCLC, possibly due to underlying sex differences in the hormone-mediated immune response. However, our results should be interpreted with caution and require confirmation, since the evidence was largely indirect and some estimates did not meet the threshold for clinical relevance. PROSPERO CRD42024597267

Authors

Institutions

Publication Details

Journal
Systematic Reviews
Published
2026-11-14
DOI
https://doi.org/10.1186/s13643-026-03387-4
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immunotherapy efficacy and patient’s sex in advanced or metastatic non-small cell lung cancer: a systematic review and network meta-analysis

Claudia Specchia, Paolo Chiodini, Vincenzo Bagnardi, Cinzia Del Giovane et al.
Systematic Reviews
Cancer Immunotherapy and Biomarkers
article

Immunotherapy efficacy and patient’s sex in advanced or metastatic non-small cell lung cancer: a systematic review and network meta-analysis

Claudia Specchia, Paolo Chiodini, Vincenzo Bagnardi, Cinzia Del Giovane, Chiara Oriecuia, Eleonora Pagan, Laura Pala, Fabio Conforti, Fabrizio Natali, Isabella Sala
article en

Abstract

Immune checkpoint inhibitors (ICIs), particularly anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1), alone or combined with chemotherapy (CT), are the gold standard for first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC). Guidelines strongly recommend anti-PD-1/PD-L1 (anti-PD-(L)1) monotherapy when PD-L1 tumor proportion score (TPS) is ≥ 50%. Emerging evidence suggests that also sex may influence ICI efficacy. The objective of this study was to estimate sex-based differences in the relative efficacy between anti-PD-(L)1 + CT and anti-PD-(L)1 monotherapy. This study is a systematic review and network meta-analysis of phase II/III randomized controlled trials evaluating ICI-based regimens containing anti-PD-(L)1 or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), alone or combined with CT, versus any control arm in advanced NSCLC, focusing on sex-specific treatment effects. Fifty trials including 29,002 patients were analyzed. For each treatment comparison, differences between males and females were assessed by calculating the ratio of hazard ratios (HRs) for males (HR-M) versus females (HR-F), separately for overall survival (OS) and progression-free survival (PFS). For OS, anti-PD-(L)1 + CT significantly improved outcomes in females compared to anti-PD-(L)1 monotherapy [HR-F (95% CI) = 0.84 (0.73–0.96)], while no significant difference was seen in males [HR-M = 0.99 (0.90–1.10)]. The pooled ratio of hazard ratios favored females [Ratio-HR = 1.20 (1.01–1.42), p = 0.04]. Similar trends were observed for PFS. Anti-CTLA-4, whether combined with CT, anti-PD-(L)1, or both, did not yield superior outcomes compared to anti-PD-(L)1 monotherapy. These findings suggest that sex may modulate the efficacy of ICI in advanced NSCLC, possibly due to underlying sex differences in the hormone-mediated immune response. However, our results should be interpreted with caution and require confirmation, since the evidence was largely indirect and some estimates did not meet the threshold for clinical relevance. PROSPERO CRD42024597267

Systematic Reviews
University of Bern (CH), University of Modena and Reggio Emilia (IT), Humanitas University (IT), University of Campania "Luigi Vanvitelli" (IT), Humanitas Gavazzeni (IT), University of Milano-Bicocca (IT), University of Brescia (IT)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon